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Introduction
Breast cancer incidence increases with age, with the vast 
majority of women diagnosed after the age of 40 years 
[1]. Nevertheless, approximately 7% of women diagnosed 
with breast cancer between 2000 and 2005 were below 
the age of 40 [2]. Interestingly, breast cancer risk factors, 
clinical outcomes, and tumor biology are somewhat 
diﬀ  erent in the subgroup of women below 40, suggesting 
that breast cancer in young women represents a distinct 
entity [3-7]. Th  e  deﬁ  nition of a ‘young woman’ in the ﬁ  eld 
of breast oncology varies, with most articles referring to 
women under either age 35 or 40 years as ‘young’.
Epidemiology
Th   e incidence of breast cancer in younger women diﬀ  ers 
according to race. Overall, breast cancer is more common 
in Caucasian women than in African Americans; however, 
in women under the age of 35, breast cancer is more than 
twice as common in African American women. Premeno-
pausal African American women are more likely to have 
hormone receptor negative tumors (and even more 
speciﬁ  cally tumors of the basal phenotype) compared to 
Caucasian women [3,8]. Young African American women 
are more likely to be diagnosed at a more advanced stage 
than young Caucasians; however, after adjusting for 
stage, survival appears equivalent between races [4].
Delayed childbirth (ﬁ   rst child after age 30 years) is 
known to be a risk factor for breast cancer in women 
older than 35. Conversely, early childbearing seems to be 
a risk factor for developing breast cancer before the age 
of 35. Th   is discrepancy could possibly be explained by the 
transient increase in breast cancer risk that occurs 
around 2 to 7 years following a pregnancy, but more 
infor  mation is needed about this association [3].
Th  e characteristics of tumors that arise in women 
under the age of 35 diﬀ  er from those that arise in pre-
menopausal women who are older than 35. Women 
younger than 35 have a lower rate of ductal carcinoma in 
situ, likely due to detection bias (women in this age range 
do not typically have screening mammograms) [4]. 
Tumors in women younger than 35 are more likely to be 
of a higher histological grade [4] and to be classiﬁ  ed as 
estrogen receptor (ER) and progesterone receptor negative 
[5,6]. In addition, young women are more likely to have 
local recurrences, to be diagnosed at a more advanced 
stage, and to have an inferior 5 year survival compared to 
their older premenopausal counterparts [4,6,7].
Th  ese diﬀ  erences in breast cancer risk factors, tumor 
characteristics, and clinical outcomes suggest that breast 
cancer arising in young women may be a distinct clinical 
entity. A study by Anders and colleagues [5] looked at 
tumor gene expression between two age speciﬁ  c cohorts 
(young, ≤45 years; and older, ≥65 years), and identiﬁ  ed 
367 gene sets that could diﬀ  erentiate tumors in young 
women from tumors in older women. Th   is suggests that 
breast cancer in young women may be distinct with a 
unique underlying biology.
Radiographic diagnosis
Women under the age of 35 do not typically undergo 
breast cancer screening unless they are at high risk for 
the development of breast cancer. For this reason, breast 
cancer cases usually present with breast complaints [9]. 
Th   e sensitivity of a mammogram is low in this population 
due to the increased density of a young woman’s breasts, 
which obscures ﬁ   ndings on mammograms. Mammo-
grams have not been shown to be clinically beneﬁ  cial or 
cost eﬀ  ective in the evaluation of breast symptoms in 
women under the age of 35 [10-12]. An ultrasound is a 
more sensitive imaging tool in young women and has the 
Abstract
Although uncommon, breast cancer in young women 
is worthy of special attention due to the unique and 
complex issues that are raised. This article reviews 
specifi  c challenges associated with the care of 
younger breast cancer patients, which include fertility 
preservation, management of inherited breast cancer 
syndromes, maintenance of bone health, secondary 
prevention, and attention to psychosocial issues.
© 2010 BioMed Central Ltd
Breast cancer in young women
Courtney A Gabriel1 and Susan M Domchek2*
REVIEW
*Correspondence: Susan.domchek@uphs.upenn.edu
2Abramson Cancer Center, University of Pennsylvania, 3 West Perelman Center, 
3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article
Gabriel and Domchek Breast Cancer Research 2010, 12:212 
http://breast-cancer-research.com/content/12/5/212
© 2010 BioMed Central Ltdadded beneﬁ  t of distinguishing solid masses from simple 
and complex cysts [9,13].
Currently, the American Cancer Society recommends a 
screening breast MRI for women with a 20 to 25% life-
time risk of breast cancer, which includes women with 
familial breast cancer syndromes (discussed below) and 
those who have received chest radiation for Hodgkin’s 
lymphoma [14]. Breast MRI has high sensitivity for malig-
nant lesions; however, speciﬁ  city is low, which can lead to 
unnecessary biopsies. In women in high risk groups, the 
beneﬁ  ts of MRI are considered to outweigh the risks of 
unnecessary biopsies. MRIs have also been shown to be 
more sensitive than mammograms, particu  larly in women 
with dense breasts [15]; however, accord  ing to American 
Cancer Society guidelines, breast density alone is not 
justiﬁ  cation for MRI screening at the current time.
In addition to considerations of MRI for primary 
screening, at the current time there is insuﬃ   cient 
evidence to recommend for or against a breast MRI for 
women with personal histories of breast cancer [14] who 
do not have a BRCA1 or BRCA2 mutation.
Genetics
Breast cancer in a woman under age 35 years should 
prompt one to consider familial breast cancer syndromes 
and genetic testing for BRCA1/2 mutations and, less 
commonly, TP53 mutations. In a population-based case 
control study, the likelihood that a woman with breast 
cancer under the age of 35 had a detectable BRCA1/2 
mutation was 9.4% (compared to a population prevalence 
of 0.2%) [16]; these ﬁ  ndings have been demonstrated by 
other studies as well. A family history of breast and/or 
ovarian cancer or Ashkenazi Jewish ancestry makes the 
probability of having a mutation even higher.
Tumor characteristics can help identify women who 
are likely to carry a BRCA1 mutation. High grade triple 
negative breast cancers (ER negative, progesterone 
receptor negative, and Her2 negative) are more common 
in women with BRCA1 mutations, whereas pathologic 
and immunohistochemical features of tumors associated 
with BRCA2 mutations are similar to those of sporadic 
cases [17]. A French study found the prevalence of 
BRCA1 mutations in women under age 35 years with 
triple negative and poorly diﬀ   erentiated tumors to be 
28.6% (4 out of 14) regardless of family history [18]. 
Similarly, Lakhani and colleagues [17] derived BRCA1 
mutation carrier probabilities on the basis of ER status 
and tumor grade, and determined that a woman between 
the ages of 30 and 34 with an ER-negative, grade 3 tumor 
has a 26.5% chance of harboring a BRCA1 mutation 
compared with a 5% chance in women of the same age 
range with any tumor type (Table 1).
Women who test positive for a BRCA1/2 mutation have 
a 40 to 50% chance of developing a second primary breast 
cancer [19-21]. BRCA 1/2 carriers are also at increased 
risk for ovarian cancer, with a lifetime risk of 40 to 50% in 
BRCA1 carriers and 10 to 20% in BRCA2 carriers [22-24]. 
Studies have shown that a prophylactic bilateral salpingo-
oophorectomy (BSO) can reduce the risk of ovarian 
cancer by as much as 80 to 96% [25,26], decrease the risk 
of developing a second primary breast cancer [21], and 
also reduce short-term mortality [27]. For these reasons, 
a prophylactic BSO is recommended when childbearing 
is complete. Yearly breast MRIs, in addition to yearly 
mammograms, are recommended for screening in 
BRCA1/2 mutation carriers [14]. Due to the high risk of a 
second primary, many BRCA1/2 mutation carriers 
choose to undergo a prophylactic bilateral mastectomy 
(PBM) in the setting of unilateral disease. Th  e risks, 
beneﬁ   ts, and controversies surrounding PBM are 
discussed below in the section ‘Secondary prevention’.
Although very rare, Li-Fraumeni syndrome (LFS) 
should also be considered when a very young woman is 
diagnosed with breast cancer. LFS is a highly penetrant, 
autosomal dominant condition characterized by early 
onset breast cancer and a variety of other rare tumors, 
including sarcoma, brain tumors, and adrenocortical 
carcinoma [28-30]. Many families meeting strict criteria 
for LFS have identiﬁ  able germline mutations in the TP53 
gene [31,32]. Nearly one-third of breast cancers in TP53 
mutation positive families occur prior to age 30 years 
[33]. Knowledge of the presence of a TP53 mutation may 
help make decisions about breast cancer therapy, 
especially since radiation may substantially increase an 
LFS patient’s risk for a second primary malignancy [34].
In a recent study, Gonzalez and colleagues [35] exam-
ined the characteristics of 525 patients whose samples 
were submitted for clinical TP53 genetic testing, of 
whom 91 (17%) had detectable mutations. Several work-
ing deﬁ  nitions for LFS exist for identifying families with 
TP53 mutations; these consider age of onset of cancer 
diagnosis, type of cancer, and cancer in ﬁ  rst and second 
degree relatives. In this study, two of these deﬁ  nitions, 
the classic LFS criteria and the Chompret’s criteria, 
identiﬁ   ed 95% of patients with TP53 mutations [35] 
Table 1. Predicted probabilities of a BRCA1 mutation based 
on age and tumor characteristics [17]
Age  All histologies  ER-negative and
(years)  (%)  high grade tumors (%)
<30 8  35
31-34 5 26.5
35-39 2 6.6
40-44 1.5 3.7
45-49 1 2.5
50-59 0.3 0.9
ER, estrogen receptor.
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family history in ﬁ  rst or second degree relatives, 1 of 14 
(7%) had a detectable mutation. A second study found no 
detectable mutations in 95 unselected BRCA1/2 negative 
women diagnosed with breast cancer under the age of 30 
[36].
Although de novo TP53 mutations have been reported 
in individuals without a family history [37,38] such de 
novo mutations are uncommon and, therefore, there is 
currently insuﬃ   cient evidence to routinely recommend 
TP53 mutation testing in breast cancer patients under 
the age of 30 in the absence of a personal or family 
history suggestive of LFS. Since the use of the classic LFS 
and Chompret’s criteria in combination have a high 
sensitivity in identifying individuals with TP53 muta-
tions, individuals meeting their criteria should be 
referred for testing [35] (Table 2).
Treatment
Young women are generally treated similarly to their 
older counterparts. Options for local therapy include a 
mastectomy or breast conserving surgery followed by 
radiation. As in older women, factors guiding surgical 
decisions include tumor size, location, ability to achieve a 
good cosmetic outcome, prior radiation or any contra-
indication to radiation, and patient preference. However, 
younger women have higher local recurrence rates than 
older women when treated with breast conservation [39-
41]. In an analysis of two large randomized trials com-
paring mastectomy versus breast conservation plus 
radiation, Voogd and colleagues [39] found that women 
under age 35 years treated with breast conservation had a 
nine times greater risk of recurrence than women over 
the age of 60 (hazard ratio, 9.24; 95% conﬁ  dence interval 
(CI), 3.74 to 22.81); however, younger patients treated 
with a mastectomy did not have an increased recurrence 
rate compared to older patients. Freedman and 
colleagues [41] retrospectively analyzed risk factors for 
local recurrence after breast conservation plus radiation 
and found that in women under the age of 35 whose 
excised tumors had both negative margins and a non-
extensive intraductal component, the rate of local 
recurrence was similar to that of older women. Th  is 
ﬁ  nding suggests that the increased risk of local recur-
rence in this age group may be due to the extensive 
intraductal components of the tumors and diﬃ   culty in 
achieving negative margins in young patients.
In addition to appropriate radiotherapy, adjuvant 
therapy with chemotherapy and/or hormonal therapy 
should be strongly considered in young women. A Danish 
study showed that young women with early stage disease 
who were not treated with cytotoxic therapy had an 
increased risk of dying compared to older age groups. 
Th   is risk increased with decreasing age of diagnosis, with 
those under the age of 35 having the poorest prognosis. 
In contrast, young women who did receive cytotoxic 
therapy had a comparable prognosis to their older counter-
parts [42]. In another study, women under the age of 30 
with stage I disease had a particularly poor relapse-free 
survival compared to older controls, presumably because 
very few of these women received adjuvant chemotherapy 
[43].
Women who achieve chemotherapy-induced amenor-
rhea have a better prognosis than women who retain 
their menses [44,45]. Th  e NASBP B-30 trial (National 
Surgical Adjuvant Breast and Bowel Project Protocol 
B-30) looked at the eﬃ   cacy of three diﬀ  erent adjuvant 
chemotherapy regimens containing doxorubicin, cyclo-
phos  phamide, and docetaxel (one regimen did not 
contain cyclophosphamide). Th  e study’s secondary aim 
was to correlate chemotherapy-induced amenorrhea with 
survival in premenopausal women. Overall survival was 
signiﬁ  cantly improved in women who achieved at least 
6 months of chemotherapy-induced amenorrhea, regard-
less of chemotherapy, and, surpris  ingly, regardless of 
hormone receptor status [44]. Th   ese data suggest that the 
therapeutic eﬀ  ects of chemotherapy are, at least in part, 
due to ovarian suppression. Th  e  eﬀ  ect of chemotherapy 
Table 2. Classifi  cation schemes for Li-Fraumeni syndrome
Scheme 
Classic LFS [29]  Proband diagnosed with sarcoma before 45 years of age, AND
  A fi  rst-degree relative with cancer before 45 years of age, AND
  Another fi  rst- or second-degree relative with any cancer diagnosed under 45 years of age or with sarcoma at any age
 
Chompret’s [112,113]  I. Proband with sarcoma, brain tumor, breast cancer, or adrenocortical carcinoma before age 36 years, AND at least one fi  rst or 
  second degree relative with cancer (other than breast cancer if the proband has breast cancer) under the age of 46 years or a 
  relative with multiple primaries at any age
  II. Proband with multiple primary tumors, two of which are sarcoma, brain tumor, breast cancer, and/or adrenocortical carcinoma, 
  with the initial cancer occurring before the age of 36 years, regardless of the family history
  III. Proband with adrenocortical carcinoma at any age of onset, regardless of the family history
LFS, Li-Fraumeni syndrome.
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patient, with young premenopausal women (<35 years) 
less likely to achieve amenorrhea with chemotherapy 
compared with older premenopausal women [46,47]. It is 
unknown whether chemotherapy can be replaced by 
ovarian suppression alone (such as with a luteinizing 
releasing hormone (LHRH) agonist). In patients with 
hormone responsive tumors, four studies suggest that the 
use of a LHRH agonist in the adjuvant setting is as 
eﬃ     cacious as chemotherapy with fewer side eﬀ  ects 
[48-53]. However, these studies all used older chemo-
therapy regimens (that is, cyclophosphamide, metho-
trexate, ﬂ  uor  ouracil (CMF)) with  out subsequent hormonal 
therapy; thus, it is currently unclear how LHRH agonists 
would compare against third generation regimens plus 
tamoxifen [54].
Although the therapeutic eﬀ   ects of chemotherapy 
appear to be at least partially due to eﬀ   ects on the 
endocrine system, chemotherapy alone is insuﬃ   cient for 
the treatment of hormone receptor positive tumors in 
young women [55]. Endocrine therapy should be oﬀ  ered 
to young women with hormone responsive tumors. Th  e 
usual treatment is tamoxifen, but ovarian suppression/
ablation (with LHRH analogs, oophorectomy, or ovarian 
radiation) can be used as alternative therapy or added in 
combination with tamoxifen [51,56-60]. In women who 
remain premenopausal after chemotherapy, it is currently 
unclear whether adding ovarian suppression to tamoxifen 
is superior to tamoxifen alone. Th  is is the subject of 
several randomized clinical trials, including the 
Suppression of Ovarian Function Trial (SOFT; 
NCT00917969).
Aromatase inhibitors are avoided in women who are 
premenopausal at diagnosis even if they develop chemo-
therapy-associated amenorrhea as there are concerns 
that reduced estrogen feedback to the hypothalamus and 
pituitary will stimulate gonadotropin release and thus 
ovarian stimulation. Chemotherapy-induced amenorrhea 
may not be permanent (and is less likely to be permanent 
the younger the woman is), and aromatase inhibitors can 
promote the recovery of ovarian function in these 
women. Th   us, aromatase inhibitors should be used with 
caution in women with chemotherapy-induced amenor-
rhea, and serum estradiol and gonadotropin levels should 
be serially monitored to ensure that ovarian function is 
not recovering [61]. Th  ere is some evidence that treat-
ment with an aromatase inhibitor plus ovarian suppres-
sion with an LHRH analog is eﬃ   cacious in pre  meno-
pausal women, and is at least as eﬃ   cacious as tamoxifen 
plus an LHRH agonist, as shown in the ABCSG 12 trial 
(by the Austrian Breast and Colorectal Cancer Study 
Group) [62]. How this combination com  pares to 
tamoxifen alone is currently being investigated by the 
SOFT trial (NCT00917969).
Breast cancer diagnosed during pregnancy is rare, with 
an incidence of 1 in 3,000 pregnancies [63]. Diagnosis 
and treatment of breast cancer during pregnancy requires 
special consideration and is beyond the scope of this 
review. A recent article published by Litton and colleagues 
[64] reviews the challenges in diagnosis and treatment of 
breast cancer during pregnancy.
Fertility
Preserving fertility is a concern that aﬀ  ects treatment 
decisions for many young women faced with a new 
diagnosis of breast cancer [65]. Chemotherapy can cause 
amenorrhea and, in some cases, permanent menopause. 
A recent prospective study examined diﬀ  erences  in 
chemo  therapy-induced amenorrhea among chemotherapy 
regimens (CMF; doxorubicin and cyclophosphamide 
(AC); doxorubicin, cyclophosphamide, and paclitaxel 
(ACT)). Th   e rate of chemotherapy-induced amenorrhea 
among the three regimens was similar; however, patients 
treated with CMF were less likely to resume their menses 
[46]. Th  e risk of chemo  therapy-induced menopause is 
also dependent on the patient’s age at diagnosis. Women 
under the age of 35 who undergo chemotherapy have a 
lower risk of meno  pause (approximately 15%) compared 
to, for example, a 40-year-old woman who has a greater 
than 40% risk of menopause. Tamoxifen may marginally 
increase a woman’s risk of early menopause [47]. More 
importantly, because of teratogenicity, women must wait 
until they complete treatment with tamoxifen before 
getting pregnant. Th  e optimal treatment duration is 
5 years, and fertility declines with age.
Fortunately, pregnancy after a diagnosis of early stage 
breast cancer does not appear to increase the risk of 
relapse [66]. In fact, a recent meta-analysis presented at 
the 2010 European Breast Cancer Conference suggested 
that pregnancy after a diagnosis of breast cancer is 
associated with improved survival when compared to 
breast cancer patients that do not have a pregnancy after 
their diagnosis [67]. One possible explanation for this 
supposed survival advantage is the ‘healthy mother 
eﬀ  ect,’ as women who feel healthy may be more likely to 
conceive, leading to selection bias [68]. However, there 
are also biologic theories as to why pregnancy may 
protect against relapse, such as alloimmunization against 
breast cancer cells [69], or the cytotoxic eﬀ  ects of high 
dose estrogen during pregnancy [70,71]. Nonetheless, 
pregnancy after a diagnosis of early stage breast cancer 
does not appear to decrease survival.
If a woman desires to bear children after her breast 
cancer treatment, she should be counseled on fertility 
preservation options. Fertility preservation should be 
discussed as early as possible, as these fertility procedures 
must be initiated prior to starting systemic therapy. 
Options to preserve fertility include ovarian preservation 
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fertilization, and oocyte or ovarian tissue cryopreser-
vation [72].
Ovarian preservation with LHRH analogs is the only 
fertility option that does not involve assisted reproductive 
techniques. LHRH analogs stop ovarian follicular 
development by suppressing gonadotropins, which, theo-
reti  cally, can protect a woman’s ovaries from damage 
from cytotoxic therapy. However, the eﬃ   cacy of LHRH 
analogs for fertility preservation has not yet been 
established. Several small studies have looked at the use 
of LHRH agonists given concurrently with chemotherapy 
to preserve ovarian function with mixed results. 
Randomized controlled trials are currently underway to 
evaluate this strategy in women with cancer [73].
To date, the most eﬀ   ective approach to preserve 
fertility in cancer patients is embryo cryopreservation. 
However, this procedure requires in vitro fertilization 
and, thus, a participating male partner (or sperm donor). 
Oocyte and ovarian tissue cryopreservation are emerging 
options for women who do not have a male partner at 
diagnosis. However, these methods are currently investi-
gational, and have resulted in lower pregnancy rates 
when compared to embryo cryopreservation [74-78].
Both embryo and oocyte cryopreservation require 
controlled ovarian stimulation, which is associated with a 
marked increase in estradiol levels. To avoid the potential 
risks of rising estradiol levels during ovarian stimulation, 
Oktay and colleagues [79] have developed an ovarian 
stimulation protocol using the aromatase inhibitor 
letrozole, which results in estradiol levels that are similar 
to unstimulated cycles. Oocyte and embryo yields using 
this protocol have been comparable to those using 
standard ovarian stimulation protocols, and after 23.4 
months of follow-up, recurrence and survival rates were 
comparable to unstimulated controls. Th  e lag time 
between surgery and chemotherapy was greater in the 
group undergoing stimulation, likely due to the extra 
time needed for ovarian stimulation. However, time to 
the start of chemotherapy for the group undergoing 
stimulation was well within 12 weeks, which has been 
established as an acceptable time frame between surgery 
and chemotherapy for breast cancer [80,81].
In summary, fertility preservation is possible in young 
women undergoing treatment for breast cancer. 
Oncologists should discuss options to preserve fertility 
prior to initiating systemic treatment, and refer to fertility 
specialists when appropriate.
Bone health
Women who experience chemotherapy-induced amenor-
rhea have been shown to experience a rapid decline in 
bone density compared to women who retain their 
menstrual function [82]. In one prospective study, the 
incidence of vertebral fractures was markedly increased 
in women followed from diagnosis of breast cancer 
(mean follow-up 2.1 years) compared to age-matched 
controls [83]. For this reason, there has been recent 
interest in preventing bone loss in premenopausal 
women undergoing treatment for breast cancer.
Two randomized trials have shown that zoledronic 
acid, an intravenous bisphosphonate, prevents bone loss 
in premenopausal women undergoing treatment for 
breast cancer. Th   e zoledronic acid was well tolerated, and 
there were no reports of renal insuﬃ   ciency  or  osteo-
necrosis of the jaw in either trial [84,85]. Additionally, 
preclinical and clinical studies suggest that bisphos-
phonates may have antitumor and antimetastatic proper-
ties [86-89]. In the ABCSG 12 trial, 1,803 premenopausal 
women receiving adjuvant hormonal therapy for early 
breast cancer were randomly assigned to receive 
goserelin plus tamoxifen or anastrazole with or without 
zolendronic acid. Th   ere was no diﬀ  erence in disease free 
survival between the two hormonal therapy groups; 
however, the addition of zolendronic acid led to a 
signiﬁ  cant improvement in disease-free survival (hazard 
ratio, 0.64; 95% CI, 0.46 to 0.91; P = 0.01), and insigni-
ﬁ  cant trend towards overall survival (hazard ratio, 0.60; 
95% CI, 0.32 to 1.11; P = 0.11). Th   is study only included 
women with endocrine responsive tumors who did not 
receive chemotherapy, so it is unknown if these results 
are generalizable to all women with breast cancer [62]. 
Conversely, a meta-analysis evaluating the eﬀ  ect  of 
clodronate, another bisphosphate, on breast cancer 
outcomes showed no diﬀ  erence in overall survival, bone 
metastasis free survival, and non-skeletal metastasis free 
survival in those receiving adjuvant clodronate compared 
to those who did not receive adjuvant bisphosphonate 
treatment [90]. Currently, there are no formal guidelines 
regarding the use of bisphosphonates in the adjuvant 
treatment of breast cancer. Results from ongoing studies 
(AZURE, NSABP-B-34, S0307 - all of which are closed to 
accrual) are expected to clarify the role of bisphos-
phonates in maintaining bone health and improving 
breast cancer outcomes.
Secondary prevention
Women treated for breast cancer are at increased risk of 
developing a contralateral breast cancer (CBC), with 
young age being an important risk factor [91-95]. In 
addition, the local recurrence rate is higher in young 
women treated with breast conservation compared to 
their older counterparts [39,40]. Guidelines recommend 
that women with a history of breast cancer have yearly 
mammograms to screen for CBCs and local recurrences. 
However, mammograms are less sensitive in younger 
women due to increased breast density [10-12]. Although 
MRIs are more sensitive than mammograms in young 
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for young women with a personal history of breast cancer 
[14]. To decrease their risk of local recurrence and CBC, 
some women choose to have PBM for unilateral disease. 
Multiple studies have shown that a PBM reduces the risk 
of a CBC by as much as 95% [96-98]. A recent population-
based study has shown that the proportion of women 
who choose to have a PBM is increasing, and has more 
than doubled between the years 1998 and 2003 [99]. Age 
has been shown to be an important predictor in the 
selection of bilateral mastectomy, with women younger 
than 40 years more likely to have this procedure [100]. 
Although a PBM can dramatically decrease the risk of a 
CBC, evidence that the procedure improves disease-
speciﬁ  c or overall survival is lacking [101]. One recent 
study, based on data from the Surveillance, Epidemiology 
and End Results (SEER) program, has suggested that 
bilateral mastectomy at the time of a unilateral breast 
cancer diagnosis may improve survival in women under 
the age of 50 with triple negative tumors [102], but more 
data are needed.
BRCA 1/2 mutation carriers have an even higher risk 
for developing a second primary breast cancer [19-21]. 
Both prophylactic BSO and tamoxifen use have been 
shown to decrease the risk of a second primary [21]. A 
retrospective cohort study that com  pared BRCA1/2 
mutation carriers with breast cancer who underwent a 
PBM with those who did not showed that a PBM reduced 
the risk of developing a CBC by 91%. After adjustment 
for BSO uptake, there was no diﬀ   erence in overall 
survival among the two groups [103]. PBMs are not 
without complications, which occur more frequently in 
women undergoing immediate reconstruction [104]. For 
these reasons, in women with BRCA1/2 mutations and in 
sporadic cases, PBMs are considered an option rather 
than a mandate and remain a personal decision. Patients 
should be aware of the risks, beneﬁ  ts, and uncertainties 
of this procedure.
Observational studies suggest that some lifestyle and 
dietary factors are associated with breast cancer prog-
nosis. Physical activity and maintaining a healthy weight 
are associated with a decreased risk of recurrence [105]. 
Vitamin D deﬁ   ciency has been associated with an 
increase in distant recurrence and death in women 
treated for early stage breast cancer [106]. Although there 
are no randomized trials that tell us whether exercise 
programs, maintaining a healthy weight, or vitamin D 
supplementation improve prognosis, in otherwise 
healthy women, there appear to be few downsides to 
these interventions.
Psychosocial issues
A diagnosis of breast cancer is distressing at any age but 
younger patients seem to experience a greater degree of 
psychological distress than their older counterparts 
[107]. A retrospective study looking at quality of life in 
577 breast cancer survivors who were under age 50 years 
at diagnosis found that women younger than 35 reported 
more emotional distress and less energy than older 
survivors even years after initial treatment. Women who 
experienced treatment-induced menopause reported 
lower health perceptions than their peers. African 
American women and women who were either married 
or had a stable partner were less likely to experience 
emotional distress [108]. It is not known why younger 
breast cancer patients suﬀ  er more emotionally than older 
patients. It has been theorized that breast cancer is 
viewed as a disease of older women and a diagnosis in 
this age group is an emotional shock. In addition, 
younger women often have more physical demands - 
such as taking care of young children and/or working full 
time - which may make it especially diﬃ   cult to endure 
treatment [107,108].
Concern over loss of fertility may also contribute to the 
emotional distress experienced by younger breast cancer 
survivors [65]. Sexual dysfunction, most notably vaginal 
dryness, is also a common complaint among breast 
cancer survivors [109]. Breast cancer survivors who have 
had a mastectomy as opposed to breast conservation 
surgery report poor body image, which may contribute 
further to sexual dysfunction [110]. In conclusion, 
younger women are at high risk for emotional distress 
when faced with a diagnosis of breast cancer. Clinicians 
should consider early referral to support and counseling 
services in this high risk group.
Th   e Young Survival Coalition [111] is an international 
organization dedicated to increasing awareness and 
providing resources for young women diagnosed with 
breast cancer under the age of 40. Th  rough  this 
organization, young women can ﬁ   nd local support 
groups and community events geared towards young 
women with breast cancer, which can hopefully reduce 
the sense of isolation felt when diagnosed with this 
disease at such a young age.
Conclusion
Management of young women with breast cancer diﬀ  ers 
from that of their older counterparts. Breast cancers in 
women under ages 35 to 40 years have more aggressive 
features, tend to be diagnosed at a later stage, and have 
inferior outcomes. Diﬀ  erences in risk factors and gene 
expression suggest that breast cancer in young women 
may be a distinct entity. Radiographic diagnosis in this 
population is challenging due to increased breast density. 
Genetic testing for the BRCA1 and BRCA2, and in certain 
cases, TP53 mutations, should be considered. Treatment 
is generally the same as for older women; however, the 
optimal type of hormonal therapy is currently unknown 
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is often a top concern for many women. Th   ey should be 
referred to a fertility specialist as early as possible - 
deﬁ  nitely prior to initiating systemic therapy. Treatment 
related menopause can lead to a rapid decline in bone 
density, and there may be a future role for the use of 
bisphosphonates in the adjuvant setting to both maintain 
bone health and prevent breast cancer recurrence. 
Prophylactic contralateral mastectomies are increasingly 
pursued, but it is unclear if they improve survival. Lastly, 
young women with breast cancer are at greater risk for 
psychological distress. Clinicians should consider early 
referral to support services in this high risk group.
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